Pharmaceutical News

RSS

New MS drug withdrawn from the market

Two patients involved in clinical trials of Tysabri, have contracted a rare and fatal disease, Elan’s multiple sclerosis (MS); one has already died. Withdrawal of the drug, eliminates all hope that it will be allowed back on the market this year, or ever.

8 Mar 2005

Thalidomide - new treatment for cancer

Thalidomide, famous in the 60's because of limb deformities in babies born to women who had taken it for morning sickness, was withdrawn in 1961. Now doctors say it could be used as a treatment for cancer.

8 Mar 2005

Web site offers fast access to drugs

A new web site run by pharmaceutical companies can help direct Indiana residents to prescription drug programs that offer free or discounted medications. Governor Mitch Daniels, a former executive at Eli Lilly and Company, says it's a safer alternative to importing drugs from other countries.

8 Mar 2005

Biomedical engineers, chemists collaborate on novel method to design better medicines

The ability to select and develop compounds that act on specific cellular targets has just gained a computational ally -- a mathematical algorithm that predicts the precise effects a given compound will have on a cell's molecular components or chemical processes.

8 Mar 2005

U.S Marshals action affects Glaxo share price

Early this month, U.S. marshals seized batches of Paxil CR and Avandamet at manufacturing and distribution sites in Puerto Rico and Knoxville, Tennessee.

8 Mar 2005

AIDS drug pricing complaint in South Africa against GlaxoSmithKline moves forward

A landmark South African legal complaint against British drug maker GlaxoSmithKline (GSK) over its AIDS drug pricing and policies in that country will proceed following an order late last week by South Africa's Competition Tribunal that will allow the complaint to go forward.

8 Mar 2005

Nano-enabled drug discovery solutions will generate revenues of $1.3 billion in 2009

According to a new report by NanoMarkets, an industry consultancy based here, nano-enabled drug discovery solutions will generate revenues of $1.3 billion in 2009 and grow to $2.5 billion in 2012.

8 Mar 2005

Cymbalta improves cognitive function in elderly patients with depression

Elderly patients with depression treated with Cymbalta (duloxetine hydrochloride), 60 mg once daily, had twice as much improvement in verbal learning and recalling information than those given a sugar pill, according to new research presented Saturday at the annual meeting of the American Association for Geriatric Psychiatry.

8 Mar 2005

Revlimid results look promising for multiple myeloma patients

The Multiple Myeloma Research Foundation (MMRF) applauded today's Celgene announcement regarding Revlimid, a new class of novel immunomodulatory drugs currently being evaluated to treat a broad range of hematology and oncology conditions, including multiple myeloma.

8 Mar 2005

Battle in the Senate over FDA

In the congressional battle over the safety of America's prescription drugs, two University of Washington experts with opposing views have been enlisted into the fray.

7 Mar 2005

Neuren and Metabolic collaborate to develop range of nerve repair compounds

Neuren Pharmaceuticals Ltd (Neuren) and Metabolic Pharmaceuticals Ltd (Metabolic) have announced that the two companies have agreed to collaborate to co-develop Neuren's class of Neuro-regenerative Peptides (NRPs) for the treatment of degenerative conditions such as peripheral neuropathy, motor neuron disease and repairing the brain or nerves after injuries such as spinal cord injury.

7 Mar 2005

International expert group discusses alternatives to COX-2 inhibitors

International group of pain specialists meets to develop recommendations for the treatment of chronic moderate-to-severe pain in the wake of the global withdrawal of rofecoxib (Vioxx) and concerns regarding use of other COX-2 inhibitors.

7 Mar 2005

Opportunities for European pharmaceutical and biotechnology companies in Indian and Chinese markets

Despite having over a third of the world's population, Asia accounts for only one fifth of global pharmaceutical drug consumption. As income levels rise, demand from this large population base is set to burgeon, opening up new growth opportunities for pharmaceutical and biotechnology companies.

7 Mar 2005

Australian biotech, Bionomics acquires central nervous system (CNS) business

Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.

6 Mar 2005

Batches of the drugs Paxil and Avandamet seized by federal officials

Batches of the drugs Paxil CR and Avandamet United States, were seized by marshals at manufacturing and distribution plants in Tennessee and Puerto Rico after federal officials said the manufacturer failed to correct violations of production safety standards.

5 Mar 2005

FDA has accepts new drug application for Exubera (inhaled human insulin powder)

Dr. John Patton, co-founder and chief scientific officer for Nektar reported that Pfizer and The Sanofi-Aventis Group have announced that the FDA has accepted for filing a new drug application for Exubera (inhaled human insulin powder).

3 Mar 2005

Antidepressants prescribed to children will have Black Box labels warnings

Antidepressants prescribed to children should have "Black box" labels warnings, which are reserved for the most dangerous drugs, of the increased risk of suicide that they pose. This will happen mid-March, five months after the Food and Drug Administration ordered it.

3 Mar 2005

FDA issues information on the risks and benefits of Crestor

The U.S. Food and Drug Administration (FDA), today issued public health advice, patient information, and professional healthcare information on the risks and benefits of Crestor (Rosuvastatin calcium), a cholesterol-lowering drug.

2 Mar 2005

FDA wants full authority to control labeling for drugs

Sandra L. Kweder, FDA's deputy director for new drugs, wants Congress to issue the FDA with the authority to control labeling for drugs to stop the prolonged disputes on this matter.

2 Mar 2005

UK Government stockpiles anti-viral medicine Tamiflu from Roche

In an attempt to prevent the spread of the influenza pandemic birdflu the U.K. government will buy 200 million pounds ($384 million) worth of the anti-viral medicine Tamiflu from Roche, one of Switzerland's largest drug companies. The influenza pandemic could kill more than 50,000 people in the country.

1 Mar 2005